Cancer charities have slammed the National Institute for Health and Clinical Excellence's (Nice) decision to reject a drug that prolongs the life of prostate cancer suffers for being too expensive.
Nice released its draft guidance saying that abiraterone's cost of at least £63,200 per quality-adjusted life year (QALY) was too much for the organisation to recommend for NHS use. However, this has...
Time limits removed
Unlimited CBT and counselling
'Existing PMI customers will require advice'
'Quick, specialised support'
Private medical insurance publisher, Craigdallie of West Sussex, has published the 2018 edition of the PMI Handbook for professional advisers seeking information on the different plans available in the UK market.
As important as DB transfers
Customer numbers rise an average 3.1% across all providers
It’s The Pro Adviser Podcast
Defer to 2021/2022